SCHEMBL301766

SCHEMBL301766

CC1CCCCC1C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.62
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA4 P22748 1/20 0.42
MEN1 O00255 1/20 0.41
BLM P54132 1/20 0.41
KMT2A Q03164 1/20 0.41
PEPD P12955 1/20 0.40
ALDH1A1 P00352 2/20 0.39
LMNA P02545 1/20 0.39
KDM4E B2RXH2 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13952183 1.00 EPHX1 (0.62) EPHX1CA1CA2CA4MEN1
SCHEMBL791505 1.00 EPHX1 (0.62) EPHX1CA1CA2CA4MEN1
SCHEMBL265072 1.00 EPHX1 (0.62) EPHX1CA1CA2CA4MEN1
SCHEMBL10556768 1.00 EPHX1 (0.62) EPHX1CA1CA2CA4MEN1
SCHEMBL3382944 1.00 EPHX1 (0.62) EPHX1CA1CA2CA4MEN1
SCHEMBL265657 1.00 EPHX1 (0.62) EPHX1CA1CA2CA4MEN1
SCHEMBL9885352 1.00 EPHX1 (0.62) EPHX1CA1CA2CA4MEN1
SCHEMBL11930055 1.00 EPHX1 (0.62) EPHX1CA1CA2CA4MEN1
SCHEMBL6917395 0.97 EPHX1 (0.60) EPHX1CA1CA2CA4MEN1
SCHEMBL12529955 0.97 EPHX1 (0.60) EPHX1CA1CA2CA4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 704 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
CN-118661881-A 6-Methyl nicotine salt preparation and preparation method thereof, buccal product, atomization matrix and electronic atomization device 爱奇迹创造有限公司 2024-09-20 CN claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
EP-3688124-B1 ESTER COMPOUNDS, LUBRICATING OIL COMPOSITIONS CONTAINING SAME AND PROCESSES FOR MAKING SAME EXXONMOBIL CHEMICAL PATENTS INC (US) 2023-10-25 EP claimed
CN-115502075-A Construction method of high-temperature-resistant heat-conducting anticorrosive coating 中国石油化工股份有限公司 2022-12-23 CN claimed
CN-114621727-A Low-density high-flame-retardant epoxy structural adhesive for bonding battery module and preparation method thereof 湖南广信科技发展有限公司 2022-06-14 CN claimed
CN-110483992-B Low-warpage reinforced semi-aromatic high-temperature nylon composite material and preparation method thereof 株洲时代新材料科技股份有限公司 2021-11-16 CN claimed
CN-106674172-B Method for preparing hexahydrophthalic anhydride 大连理工大学 2020-02-21 CN claimed
CN-108729226-A A kind of preparation method of rapid-curing cutback raincoat cloth 枞阳县陶波雨具有限公司 2018-11-02 CN claimed
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 US claimed
EP-1655372-A2 Production of polyketides and other natural products Biotica Technology Limited (GB) 2006-05-10 EP claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 US claimed
US-20050272132-A1 Production of polyketides and other natural products BIOTICA TECHNOLOGY LIMITED (GB) 2005-12-08 US claimed
EP-1589031-A2 Production of polyketides and other natural products Biotica Technology Limited (GB) 2005-10-26 EP claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US claimed
EP-0468470-B1 Benzimidazoles, medicaments containing them and process for their preparation THOMAE GMBH DR K (DE) 1997-04-16 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10072043-B2 Inhibitors of protein tyrosine phosphatases PTPRCAP, PTPRF, PTPRS EPHX1 1402/4885CA1 4047/4885CA2 3509/4885
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 EPHX1 3259/4885CA1 102/4885CA2 32/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 EPHX1 2835/4885CA1 139/4885CA2 664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.